Background: Patients with multiple myeloma (MM) have increased risks of venous thromboembolism (VTE) and arterial thromboembolism (ATE). The risk of thrombosis differs among different treatment regimens. It is unknown if daratumumab could affect thrombosis risk.
Methods: A comprehensive search was conducted until April 2020. Events of VTE, including pulmonary embolism and deep venous thrombosis, as well as events of ATE, including acute ischemic stroke and myocardial infarction, were extracted from trials. In addition, events of thrombocytopenia and gastrointestinal (GI) bleeding were also extracted.
Results: Six trials were included in the meta-analysis. Daratumumab was associated with a lower risk of VTE compared with non-daratumumab regimen (Risk ratio [RR], 0.60; 95% confidence interval [CI], 0.40-0.91). The risk of ATE had no significant difference (RR, 0.80; 95% CI, 0.48-1.33). Daratumumab was also associated with a trend of higher risk of Grade 3/4 thrombocytopenia (RR, 1.14; 95% CI, 0.94-1.38), while the risk of GI bleeding was not significantly different (RR, 1.32; 95% CI, 0.38-4.65).
Conclusion: Daratumumab is associated with lower risk of VTE in clinical trials.
Keywords: Arterial thromboembolism; Daratumumab; Multiple myeloma; Venous thromboembolism.